# Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma

> **NCT07123545** · PHASE1,PHASE2 · RECRUITING · sponsor: **Zhejiang University** · enrollment: 20 (estimated)

## Conditions studied

- Advanced Hepatocellular Carcinoma (HCC)

## Interventions

- **BIOLOGICAL:** iNeo-Vac-P01 Personalized Neoantigen Peptide Vaccine
- **BIOLOGICAL:** iNeo-Vac-T01 Personalized T Cell Injection

## Key facts

- **NCT ID:** NCT07123545
- **Lead sponsor:** Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-01
- **Primary completion:** 2027-07-31
- **Final completion:** 2029-07-31
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07123545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07123545, "Autologous Neoantigen-Specific T-Cell Therapy for Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07123545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*